Last 12 months
Inside the activity.
1 purchase rows · 14 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 5 |
| Jan 2026 | 0 | 1 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 1 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 2 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 2 |
| Aug 2026 | 0 | 1 |
| Sep 2026 | 0 | 2 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 25, 2023 Filed May 27, 2023 01:00 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
GrantPerformance Restricted Stock Unit · Derivative | 422,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032726 · doc4.xml · derivative · entry 4 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 422,000 Underlying: Common Stock, $.01 Par Value · 422,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F4 · derivative.exercise_date: The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 4 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F4 · derivative.expiration_date: The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 4 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F4 · derivative.underlying_shares: The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Box 4 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 25, 2023 Filed May 27, 2023 01:00 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
SaleCommon Stock, $.01 Par Value | 75,000 | $4.59 | $344,467.50 |
DisclosureSEC source: 0001209191-23-032726 · doc4.xml · nonDerivative · entry 2 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,601,735 F3 · kind: Transaction occurred pursuant to a Rule 10B5-1 Plan adopted on December 5, 2022. Read SEC document |
| May 25, 2023 Filed May 27, 2023 01:00 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
GrantCommon Stock, $.01 Par Value | 345,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032726 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,676,735 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · shares: Acquired pursuant to a Restricted Stock Unit Award: 25% vests on July 15, 2024 and each yearly anniversary thereof until fully vested. Read SEC document |
| May 25, 2023 Filed May 27, 2023 01:00 UTC |
Singh Sanjay REVP Technical Operations
|
GrantPerformance Restricted Stock Unit · Derivative | 85,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032725 · doc4.xml · derivative · entry 2 Singh Sanjay R · CIK 0001953423 · EVP Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 85,000 Underlying: Common Stock, $.01 Par Value · 85,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F3 · derivative.exercise_date: The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Table II Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F3 · derivative.expiration_date: The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Table II Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F3 · derivative.underlying_shares: The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Table II Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 25, 2023 Filed May 27, 2023 01:00 UTC |
Singh Sanjay REVP Technical Operations
|
GrantCommon Stock, $.01 Par Value | 68,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032725 · doc4.xml · nonDerivative · entry 1 Singh Sanjay R · CIK 0001953423 · EVP Technical Operations 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 287,250 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · shares: Acquired pursuant to a Restricted Stock Unit Award: 25% vests on July 15, 2024 and each yearly anniversary thereof until fully vested. Read SEC document |
| May 25, 2023 Filed May 27, 2023 01:00 UTC |
Shannon James SamuelDirector
|
GrantRestricted Stock Unit · Derivative | 47,393 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032732 · doc4.xml · derivative · entry 1 Shannon James Samuel · CIK 0001485417 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,393 Underlying: Common Stock · 47,393 shares Expires 2033-05-25 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · derivative.exercise_date: Restricted stock unit vested on May 25, 2023, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. Read SEC document |
| May 25, 2023 Filed May 27, 2023 01:00 UTC |
Consiglio Ronald JDirector
|
GrantRestricted Stock Unit · Derivative | 35,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032727 · doc4.xml · derivative · entry 1 CONSIGLIO RONALD J · CIK 0001232088 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,545 Underlying: Common Stock · 35,545 shares Expires 2033-05-25 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · derivative.exercise_date: Restricted stock unit vested on May 25, 2023, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. Read SEC document |
| May 25, 2023 Filed May 27, 2023 01:00 UTC |
Binder Steven B.Chief Financial Officer
|
GrantPerformance Restricted Stock Unit · Derivative | 113,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032723 · doc4.xml · derivative · entry 2 Binder Steven B. · CIK 0001712601 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,000 Underlying: Common Stock, $.01 Par Value · 113,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F3 · derivative.exercise_date: The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Table II Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F3 · derivative.expiration_date: The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Table II Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F3 · derivative.underlying_shares: The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Table II Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 25, 2023 Filed May 27, 2023 01:00 UTC |
Binder Steven B.Chief Financial Officer
|
GrantCommon Stock, $.01 Par Value | 92,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032723 · doc4.xml · nonDerivative · entry 1 Binder Steven B. · CIK 0001712601 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 930,324 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · shares: Acquired pursuant to a Restricted Stock Unit Award: 25% vests on July 15, 2024 and each yearly anniversary thereof until fully vested. Read SEC document |
| May 25, 2023 Filed May 27, 2023 01:00 UTC |
Tross Stuart AChief People & Workpl Officer
|
GrantPerformance Restricted Stock Unit · Derivative | 113,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032731 · doc4.xml · derivative · entry 2 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 113,000 Underlying: Common Stock, $.01 Par Value · 113,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F3 · derivative.exercise_date: The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Table II Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F3 · derivative.expiration_date: The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Table II Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. F3 · derivative.underlying_shares: The performance-based restricted stock unit will vest on July 15, 2026, provided that the closing price of MannKind common stock on the Nasdaq Global Market on June 30, 2026 is not less than the closing sale price on July 1, 2023. The number of shares delivered on the vesting date, as a percentage of the target specified in Table II Box 5 above, is determined by the percentile ranking of MannKind total shareholder return (TSR) over the period from July 1, 2023 until June 30, 2026 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same three-year period, as follows: less than 25th percentile=0% of target, 25th percentile=50% of target, 50th percentile=100% of target, 75th percentile=200% percent of target, 90th percentile or higher=300% maximum. Payout values will be interpolated between the percentile rankings above. Read SEC document |
| May 25, 2023 Filed May 27, 2023 01:00 UTC |
Tross Stuart AChief People & Workpl Officer
|
GrantCommon Stock, $.01 Par Value | 92,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032731 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,024,752 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · shares: Acquired pursuant to a Restricted Stock Unit Award: 25% vests on July 15, 2024 and each yearly anniversary thereof until fully vested. Read SEC document |
| May 25, 2023 Filed May 27, 2023 01:00 UTC |
BLANK BURKHARDEVP Chief Medical Officer
|
GrantRestricted Stock Unit | 210,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032719 · doc4.xml · nonDerivative · entry 1 BLANK BURKHARD · CIK 0001073409 · EVP Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 210,000 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · shares: 4-year vesting schedule with 1/4th of shares vesting on the first anniversary of the vesting determination date and on each anniversary thereafter until fully vested on the fourth anniversary of the vesting determination date. The vesting determination date for this grant is May 24, 2023. Read SEC document |
| May 25, 2023 Filed May 27, 2023 01:00 UTC |
Kay SabrinaDirector
|
GrantRestricted Stock Unit · Derivative | 35,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032733 · doc4.xml · derivative · entry 1 Kay Sabrina · CIK 0001835895 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,545 Underlying: Common Stock · 35,545 shares Expires 2033-05-25 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · derivative.exercise_date: Restricted stock unit vested on May 25, 2023, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. Read SEC document |
| May 25, 2023 Filed May 27, 2023 01:00 UTC |
Grancio JenniferDirector
|
GrantRestricted Stock Unit · Derivative | 35,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032729 · doc4.xml · derivative · entry 1 Grancio Jennifer · CIK 0001807888 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,545 Underlying: Common Stock · 35,545 shares Expires 2033-05-25 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · derivative.exercise_date: Restricted stock unit vested on May 25, 2023, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. Read SEC document |
| May 25, 2023 Filed May 27, 2023 01:00 UTC |
KRESA KENTDirector
|
GrantRestricted Stock Unit · Derivative | 47,393 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032721 · doc4.xml · derivative · entry 1 KRESA KENT · CIK 0001197571 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,393 Underlying: Common Stock · 47,393 shares Expires 2033-05-25 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · derivative.exercise_date: Restricted stock unit vested on May 25, 2023, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. Read SEC document |
| May 25, 2023 Filed May 27, 2023 01:00 UTC |
HOOPER ANTHONY CDirector
|
GrantRestricted Stock Unit · Derivative | 47,393 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032722 · doc4.xml · derivative · entry 1 HOOPER ANTHONY C · CIK 0001277244 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,393 Underlying: Common Stock · 47,393 shares Expires 2033-05-25 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · derivative.exercise_date: Restricted stock unit vested on May 25, 2023, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. Read SEC document |
| May 25, 2023 Filed May 27, 2023 01:00 UTC |
Friedman Michael ADirector
|
GrantRestricted Stock Unit · Derivative | 35,545 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032720 · doc4.xml · derivative · entry 1 Friedman Michael A · CIK 0001298083 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,545 Underlying: Common Stock · 35,545 shares Expires 2033-05-25 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · derivative.exercise_date: Restricted stock unit vested on May 25, 2023, but the shares will not be delivered until there is a separation of service from the board of directors of MannKind Corporation. Read SEC document |
| May 24, 2023 Filed May 25, 2023 01:00 UTC |
Thomson DavidEVP Genl Counsel & Secretary
|
SaleCommon Stock, $.01 Par Value | 95,576 | $4.68 | $447,754.44 |
DisclosureSEC source: 0001209191-23-032035 · doc4.xml · nonDerivative · entry 3 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 735,263 F3 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan. Read SEC document |
| May 24, 2023 Filed May 25, 2023 01:00 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
SaleCommon Stock, $.01 Par Value | 150,000 | $4.69 | $702,780.00 |
DisclosureSEC source: 0001209191-23-032032 · doc4.xml · nonDerivative · entry 3 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,331,735 F3 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan. Read SEC document |
| May 24, 2023 Filed May 25, 2023 01:00 UTC |
Binder Steven B.Chief Financial Officer
|
SaleCommon Stock, $.01 Par Value | 47,810 | $4.68 | $223,511.75 |
DisclosureSEC source: 0001209191-23-032034 · doc4.xml · nonDerivative · entry 3 Binder Steven B. · CIK 0001712601 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 838,324 F3 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan. Read SEC document |
| May 22, 2023 Filed May 25, 2023 01:00 UTC |
Thomson DavidEVP Genl Counsel & Secretary
|
Tax withholdingCommon Stock, $.01 Par Value | 281,414 | $4.79 | $1,347,973.06 |
DisclosureSEC source: 0001209191-23-032035 · doc4.xml · nonDerivative · entry 2 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 830,839 F2 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 22, 2023 Filed May 25, 2023 01:00 UTC |
Thomson DavidEVP Genl Counsel & Secretary
|
GrantCommon Stock, $.01 Par Value | 400,000 | $4.79 | $1,916,000.00 |
DisclosureSEC source: 0001209191-23-032035 · doc4.xml · nonDerivative · entry 1 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,112,253 F1 · kind: A previously reported restricted stock unit award granted on August 27, 2020 vested on May 22, 2023 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on May 22, 2023 was not less than the closing price on August 27, 2020 and (ii) the percentile ranking of MannKind's total shareholder return (TSR) over the period from August 27, 2020 to May 22, 2023 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period was greater than the 90th percentile. As a result, the performance objective was achieved at 300% of target, resulting in a total share delivery of 600,000 shares. The acquisition of 200,000 shares pursuant to the restricted stock award was reported in Table I of the Form 4 filed by the Reporting Person on August 31, 2020. Read SEC document |
| May 22, 2023 Filed May 25, 2023 01:00 UTC |
Tross Stuart AChief People & Workpl Officer
|
Tax withholdingCommon Stock, $.01 Par Value | 279,998 | $4.79 | $1,341,190.42 |
DisclosureSEC source: 0001209191-23-032033 · doc4.xml · nonDerivative · entry 2 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 932,752 F2 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 22, 2023 Filed May 25, 2023 01:00 UTC |
Tross Stuart AChief People & Workpl Officer
|
GrantCommon Stock, $.01 Par Value | 400,000 | $4.79 | $1,916,000.00 |
DisclosureSEC source: 0001209191-23-032033 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,212,750 F1 · kind: A previously reported restricted stock unit award granted on August 27, 2020 vested on May 22, 2023 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on May 22, 2023 was not less than the closing price on August 27, 2020 and (ii) the percentile ranking of MannKind's total shareholder return (TSR) over the period from August 27, 2020 to May 22, 2023 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period was greater than the 90th percentile. As a result, the performance objective was achieved at 300% of target, resulting in a total share delivery of 600,000 shares. The acquisition of 200,000 shares pursuant to the restricted stock award was reported in Table I of the Form 4 filed by the Reporting Person on August 31, 2020. Read SEC document |
| May 22, 2023 Filed May 25, 2023 01:00 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
Tax withholdingCommon Stock, $.01 Par Value | 500,000 | $4.79 | $2,395,000.00 |
DisclosureSEC source: 0001209191-23-032032 · doc4.xml · nonDerivative · entry 2 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,481,735 F2 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 22, 2023 Filed May 25, 2023 01:00 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
GrantCommon Stock, $.01 Par Value | 1,000,000 | $4.79 | $4,790,000.00 |
DisclosureSEC source: 0001209191-23-032032 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,981,735 F1 · kind: A previously reported restricted stock unit award granted on August 27, 2020 vested on May 22, 2023 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on May 22, 2023 was not less than the closing price on August 27, 2020 and (ii) the percentile ranking of MannKind's total shareholder return (TSR) over the period from August 27, 2020 to May 22, 2023 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period was greater than the 90th percentile. As a result, the performance objective was achieved at 300% of target, resulting in a total share delivery of 1,500,000 shares. The acquisition of 500,000 shares pursuant to the restricted stock award was reported in Table I of the Form 4 filed by the Reporting Person on August 31, 2020. Read SEC document |
| May 22, 2023 Filed May 25, 2023 01:00 UTC |
Binder Steven B.Chief Financial Officer
|
Tax withholdingCommon Stock, $.01 Par Value | 227,405 | $4.79 | $1,089,269.95 |
DisclosureSEC source: 0001209191-23-032034 · doc4.xml · nonDerivative · entry 2 Binder Steven B. · CIK 0001712601 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 886,134 F2 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 22, 2023 Filed May 25, 2023 01:00 UTC |
Binder Steven B.Chief Financial Officer
|
GrantCommon Stock, $.01 Par Value | 400,000 | $4.79 | $1,916,000.00 |
DisclosureSEC source: 0001209191-23-032034 · doc4.xml · nonDerivative · entry 1 Binder Steven B. · CIK 0001712601 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,113,539 F1 · kind: A previously reported restricted stock unit award granted on August 27, 2020 vested on May 22, 2023 upon the achievement of performance objectives established by MannKind's compensation committee at the time of the approval of the award. Specifically, (i) the closing price of MannKind's common stock on May 22, 2023 was not less than the closing price on August 27, 2020 and (ii) the percentile ranking of MannKind's total shareholder return (TSR) over the period from August 27, 2020 to May 22, 2023 relative to the TSR of the Russell 3000 Pharmaceutical & Biotechnology Index over the same period was greater than the 90th percentile. As a result, the performance objective was achieved at 300% of target, resulting in a total share delivery of 600,000 shares. The acquisition of 200,000 shares pursuant to the restricted stock award was reported in Table I of the Form 4 filed by the Reporting Person on August 31, 2020. Read SEC document |
| May 22, 2023 Filed May 25, 2023 01:00 UTC |
Sabella Lauren MEVP Chief Operating Officer
|
GrantRestricted Stock Unit | 210,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032031 · doc4.xml · nonDerivative · entry 1 Sabella Lauren M · CIK 0001360928 · EVP Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 224,184 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · shares: 4-year vesting schedule with 1/4th of shares vesting on the first anniversary of the vesting determination date and on each anniversary thereafter until fully vested on the fourth anniversary of the vesting determination date. The vesting determination date for this grant is March 27, 2023. Read SEC document |
| May 22, 2023 Filed May 31, 2023 01:00 UTC Amendment |
Binder Steven B.Chief Financial Officer
|
Tax withholdingCommon Stock, $.01 Par Value | 281,267 | $4.79 | $1,347,268.93 |
DisclosureSEC source: 0001209191-23-033054 · doc4a.xml · nonDerivative · entry 1 Binder Steven B. · CIK 0001712601 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 876,462 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Previously reported 227,405 shares were withheld. This Form 4A reports the final settlement to satisfy the tax liability with 281,267 shares withheld instead. F1 · shares: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Previously reported 227,405 shares were withheld. This Form 4A reports the final settlement to satisfy the tax liability with 281,267 shares withheld instead. Read SEC document |
| May 18, 2023 Filed May 20, 2023 01:00 UTC |
Thomson DavidEVP Genl Counsel & Secretary
|
Tax withholdingCommon Stock, $.01 Par Value | 6,001 | $4.56 | $27,364.56 |
DisclosureSEC source: 0001209191-23-031288 · doc4.xml · nonDerivative · entry 1 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 712,253 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 18, 2023 Filed May 20, 2023 01:00 UTC |
Tross Stuart AChief People & Workpl Officer
|
Tax withholdingCommon Stock, $.01 Par Value | 5,941 | $4.56 | $27,090.96 |
DisclosureSEC source: 0001209191-23-031287 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 812,750 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 18, 2023 Filed May 20, 2023 01:00 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
Tax withholdingCommon Stock, $.01 Par Value | 16,434 | $4.56 | $74,939.04 |
DisclosureSEC source: 0001209191-23-031286 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,981,735 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 18, 2023 Filed May 20, 2023 01:00 UTC |
Binder Steven B.Chief Financial Officer
|
Tax withholdingCommon Stock, $.01 Par Value | 5,972 | $4.56 | $27,232.32 |
DisclosureSEC source: 0001209191-23-031285 · doc4.xml · nonDerivative · entry 1 Binder Steven B. · CIK 0001712601 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 713,539 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 15, 2023 Filed May 15, 2023 21:01 UTC |
Sabella Lauren MEVP Chief Operating Officer
|
GrantCommon Stock,$.01 par value | 14,184 | $4.23 | $59,998.32 |
DisclosureSEC source: 0001209191-23-029518 · doc4.xml · nonDerivative · entry 1 Sabella Lauren M · CIK 0001360928 · EVP Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,184 F1 · kind: The securities were purchased through the Issuer's Market Price Stock Purchase Plan. The purchase was approved by the Company's Board of Directors on May 13, 2023. Read SEC document |
| May 15, 2023 Filed May 15, 2023 21:00 UTC |
Tross Stuart AChief People & Workpl Officer
|
GrantCommon Stock,$.01 par value | 10,000 | $4.23 | $42,300.00 |
DisclosureSEC source: 0001209191-23-029517 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 818,691 F1 · kind: The securities were purchased through the Issuer's Market Price Stock Purchase Plan. The purchase was approved by the Company's Board of Directors on May 13, 2023. Read SEC document |
| May 15, 2023 Filed May 15, 2023 21:00 UTC |
Binder Steven B.Chief Financial Officer
|
GrantCommon Stock,$.01 par value | 11,820 | $4.23 | $49,998.60 |
DisclosureSEC source: 0001209191-23-029519 · doc4.xml · nonDerivative · entry 1 Binder Steven B. · CIK 0001712601 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 719,511 F1 · kind: The securities were purchased through the Issuer's Market Price Stock Purchase Plan. The purchase was approved by the Company's Board of Directors on May 13, 2023. Read SEC document |
| May 10, 2023 Filed May 13, 2023 01:00 UTC |
Tross Stuart AChief People & Workpl Officer
|
Tax withholdingCommon Stock, $.01 Par Value | 7,781 | $4.40 | $34,236.40 |
DisclosureSEC source: 0001209191-23-029236 · doc4.xml · nonDerivative · entry 1 Tross Stuart A · CIK 0001589641 · Chief People & Workpl Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 808,691 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 10, 2023 Filed May 13, 2023 01:00 UTC |
Thomson DavidEVP Genl Counsel & Secretary
|
Tax withholdingCommon Stock, $.01 Par Value | 7,781 | $4.40 | $34,236.40 |
DisclosureSEC source: 0001209191-23-029238 · doc4.xml · nonDerivative · entry 1 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 718,254 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 10, 2023 Filed May 13, 2023 01:00 UTC |
Binder Steven B.Chief Financial Officer
|
Tax withholdingCommon Stock, $.01 Par Value | 7,781 | $4.40 | $34,236.40 |
DisclosureSEC source: 0001209191-23-029237 · doc4.xml · nonDerivative · entry 1 Binder Steven B. · CIK 0001712601 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 707,691 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 10, 2023 Filed May 13, 2023 01:00 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
Tax withholdingCommon Stock, $.01 Par Value | 21,959 | $4.40 | $96,619.60 |
DisclosureSEC source: 0001209191-23-029235 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,998,169 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| May 05, 2023 Filed May 6, 2023 01:00 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
SaleCommon Stock, $.01 Par Value | 10,000 | $4.00 | $40,000.00 |
DisclosureSEC source: 0001209191-23-027850 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 2,020,128 F1 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan. Read SEC document |
| April 03, 2023 Filed Apr 6, 2023 01:00 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
SaleCommon Stock, $.01 Par Value | 10,000 | $4.13 | $41,287.00 |
DisclosureSEC source: 0001209191-23-023542 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,030,128 F1 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan. Read SEC document |
| March 01, 2023 Filed Mar 4, 2023 02:00 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
SaleCommon Stock, $.01 Par Value | 10,000 | $5.27 | $52,748.00 |
DisclosureSEC source: 0001209191-23-016092 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,040,128 F1 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan. Read SEC document |
| November 01, 2022 Filed Nov 4, 2022 01:00 UTC |
Singh Sanjay REVP Technical Operations
|
GrantRestricted Stock Unit | 218,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-055685 · doc4.xml · nonDerivative · entry 1 Singh Sanjay R · CIK 0001953423 · EVP Technical Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 218,500 F1 · shares: Each restricted stock unit represents a contingent right to receive one share of MNKD common stock. F2 · shares: 4-year vesting schedule with 1/4th of shares vesting on the first anniversary of the vesting determination date and on each anniversary thereafter until fully vested on the fourth anniversary of the vesting determination date. Read SEC document |
| August 29, 2022 Filed Aug 30, 2022 01:00 UTC |
Thomson DavidEVP Genl Counsel & Secretary
|
SaleCommon Stock, $.01 Par Value | 7,000 | $3.67 | $25,690.00 |
DisclosureSEC source: 0001209191-22-047943 · doc4.xml · nonDerivative · entry 2 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 726,035 F2 · kind: Transaction occurred pursuant to Rule 10B5-1 Plan to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| August 27, 2022 Filed Aug 30, 2022 01:00 UTC |
Kocinsky JosephChief Technology Officer
|
Tax withholdingCommon Stock, $.01 Par Value | 12,813 | $3.73 | $47,792.49 |
DisclosureSEC source: 0001209191-22-047946 · doc4.xml · nonDerivative · entry 1 Kocinsky Joseph · CIK 0001655595 · Chief Technology Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 745,233 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| August 27, 2022 Filed Aug 30, 2022 01:00 UTC |
Binder Steven B.Chief Financial Officer
|
Tax withholdingCommon Stock, $.01 Par Value | 14,178 | $3.73 | $52,883.94 |
DisclosureSEC source: 0001209191-22-047945 · doc4.xml · nonDerivative · entry 1 Binder Steven B. · CIK 0001712601 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 714,819 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| August 27, 2022 Filed Aug 30, 2022 01:00 UTC |
Castagna MichaelDirector · Chief Executive Officer
|
Tax withholdingCommon Stock, $.01 Par Value | 35,952 | $3.73 | $134,100.96 |
DisclosureSEC source: 0001209191-22-047944 · doc4.xml · nonDerivative · entry 1 Castagna Michael · CIK 0001674282 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,048,534 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
| August 27, 2022 Filed Aug 30, 2022 01:00 UTC |
Thomson DavidEVP Genl Counsel & Secretary
|
Tax withholdingCommon Stock, $.01 Par Value | 14,178 | $3.73 | $52,883.94 |
DisclosureSEC source: 0001209191-22-047943 · doc4.xml · nonDerivative · entry 1 Thomson David · CIK 0001297976 · EVP Genl Counsel & Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 733,035 F1 · kind: Shares withheld to satisfy the tax liability incident to the vesting of previously reported restricted stock units. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.